NCT06466395View on ClinicalTrials.gov

A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias

PHASE1RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2031

Conditions
Refractory Acute LeukemiaRelapsed Acute LeukemiaUndifferentiated LeukemiaBi-Phenotypic Leukemia
Interventions
DRUG

Venetoclax

Given by PO

DRUG

Hyper-CVAD

Given by IV

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER